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Background: Macrolide antibiotics have demonstrated important anti-inflammatory and 
immunomodulatory properties in chronic rhinosinusitis (CRS) patients. However, reports of 
increased risks of cardiovascular events have led to safety concerns. We investigated the risk 
of all-cause and cardiac death, and cardiovascular outcomes, associated with macrolide use. 
 
Methodology: Observational cohort (1997-2016) using linked data from the Clinical Practice 
Research Datalink, Hospital Episodes Statistics, and the Office for National Statistics. Patients 
aged 16-80 years with CRS prescribed a macrolide antibiotic or penicillin were included, 
comparing prescriptions for macrolide antibiotics to penicillin. Outcomes were all-cause 
mortality, cardiac death, myocardial infarction, stroke, diagnosis of peripheral vascular disease, 
and cardiac arrhythmia.  
 
Results: Analysis included 320,798 prescriptions received by 66,331 patients. There were 
3,251 deaths, 815 due to cardiovascular causes, 925 incident myocardial infarctions, 859 
strokes, 637 diagnoses of peripheral vascular disease, and 1,436 cardiac arrhythmias.  A non-
statistically significant trend towards increased risk of myocardial infarction during the first 30 
days following macrolide prescription was observed (fully adjusted hazard ratio 1.60, 95% 
confidence interval: 0.95, 2.68, p=0.08). No statistically significant short- or long-term risks 
were observed for macrolide prescription. No significant risks were identified for 
clarithromycin in particular. 
 
Conclusions: Although not statistically significant, our best estimates suggest an increased 
short-term risk of myocardial infarction in patients with CRS following macrolide prescription, 
supporting previous observational evidence. However, confounding by indication remains a 
possible explanation for this apparent increased risk. We found no evidence of longer term 
increased risks. 
 







Macrolide antibiotics are commonly prescribed in primary and secondary care settings for a 
wide range of infections. In patients with chronic rhinosinusitis (CRS), macrolides have 
demonstrated important anti-inflammatory and immunomodulatory properties and currently 
have an unproven role on the basis of existing trials 1, though there is some promising evidence 
2, 3. Concerns remain about the safety of these antibiotics for this patient group, however 
previous research assessed the risk in full dose, short-term studies and not in cases of CRS at 
low doses for longer durations.  
 
Macrolides are known to prolong the QT interval, potentially increasing the short term risk of 
arrhythmia 4, 5. A number of studies have explored longer-term associations between macrolide 
antibiotics, particularly clarithromycin, and a range of cardiovascular events. Some have found 
increased risks of cardiovascular events that extend at least a year beyond the exposure to the 
antibiotic 6-9. In particular a 10-year follow-up of a randomised trial found an increased risk of 
cardiovascular mortality and other cardiovascular events 9. In contrast, a number of large 
observational studies have found no long term effects 10-13, although some found evidence of 
short term increases in risk of cardiovascular events 11-13. In particular the recent meta-analysis 
published by Wong et al 14, demonstrated that the short-term risk of cardiovascular outcomes 
associated with macrolides in observational studies was estimated at 1.79 excess myocardial 
infarctions per 1000 patients (95% confidence interval (CI): 0.88 to 3.20). This risk was not 
observed in RCTs; however, the authors comment that these trials were likely underpowered 
to detect this. No long-term cardiovascular risk (ranging from 30 days to 3 years) associated 
with macrolides was observed. A recent drug safety communication released by the U.S. Food 
and Drug Administration notes the possibility of long-term risks, citing heart problems or 
death, associated with clarithromycin in patients with heart disease 15.  
 
Objectives 
We aimed to explore the association between macrolide prescription, particularly 
clarithromycin, and a range of cardiovascular outcomes among patients with CRS (all-cause 




MATERIALS AND METHODS 
Study design and setting 
An observational cohort study was conducted using linked data from the Clinical Practice 
Research Datalink, Hospital Episodes Statistics, and the Office for National Statistics. 
Ethical approval 
Requests to access data provided by the Clinical Practice Research Datalink are subject to 
approval of the protocol by the Independent Scientific Advisory Committee (ISAC), a non-
statutory expert advisory body. Broad scientific and ethical approval for the use of primary 
care data, and established data linkages within the Clinical Practice Research Datalink (CPRD) 
data, was obtained following ISAC application; Protocol number 16_200R. 
 
Participants 
A case ascertainment algorithm was developed, using primary and secondary care diagnostic 
terms and secondary care procedures, to identify patients with CRS (see Appendix A). Patients 
were included if they were: determined to have CRS; prescribed one or more courses of either 
a macrolide antibiotic or a penicillin, or both; and aged between 16 and 80 years old at the time 
of a relevant prescription. Patients with a diagnosis of cystic fibrosis were excluded. 
 
Outcomes  
Outcomes studied were: time to all-cause death, cardiac death, fatal and non-fatal myocardial 
infarction, stroke, diagnosis of peripheral vascular disease, and cardiac arrhythmia. For non-
fatal outcomes, patients with a history of the outcome were excluded from those analyses.  
 
All-cause death was defined as a valid date of death, irrespective of cause, recorded in either 
CPRD or ONS. Date of death was taken to be the earliest recorded date of death from either 
source. Cardiac death was identified using the primary cause of death only (ICD 10th revision: 
I00-I99). Prevalent and incident events of all other study outcomes were identified using a 
combination of CPRD, HES, and ONS data, using previously-validated existing phenotyping 
algorithms developed in CALIBER 16.   
 
Exposure 
All prescriptions for a macrolide antibiotic or a penicillin for CRS cases during follow-up were 
identified using a clinician-reviewed and curated list of medications (Appendix B). An active 
comparator – penicillin (the most commonly prescribed antibiotic) – was chosen to minimise 
selection bias. All durations of prescriptions were included. Secondary analyses restricted the 
macrolide group to prescriptions of clarithromycin, for comparison with similar studies.  
 
Follow-up 
Follow-up of an individual patient began at the date at which the patient was deemed to have a 
CRS diagnosis, which was necessarily after the last of the following: current registration date 
of the patient at their general practice, the date at which the general practice was deemed to be 
providing research quality data, one year of individual research quality data, the patient’s 16th 
birthday, and the study start date (1st April 1997). Follow-up ended at the first of the following: 
the date of the patient’s transfer out of the general practice (defined as the Transfer Out Date 
in CPRD), the last collection of data from general practice (defined as the Last Collection Date 
in CPRD), the patient’s 80th birthday, the date of death (recorded in either CPRD or ONS), or 
the study end date (February 29th 2016).   
 
Data sources 
We extracted anonymized patient electronic health records from the CALIBER resource 
described and validated elsewhere 16. Briefly, CALIBER provides a platform to utilise 
longitudinal structured records from three national sources for research: The Clinical Practice 
Research Datalink (CPRD) 17, Hospital Episodes Statistics (HES), and cause-specific mortality 
from the Office for National Statistics. CPRD provides anthropometric measurements, 
laboratory tests, clinical diagnoses, symptoms, prescriptions, and medical procedures, coded 
with the Read controlled clinical terminology. The primary care practices in CPRD and the 
subset of linked practices used in the present analysis are representative of the UK primary care 
setting and have been validated for epidemiological research 17, 18. HES provides information 
about diagnoses (coded with the tenth revision of the International Classification of Diseases 
[ICD-10]) and medical procedures (coded with the 4th revision of the OPCS Classification of 
Interventions and Procedures [OPCS-4]) related to all elective and emergency hospital 
admissions across all National Health Service hospitals in England. ONS provides a national 
mortality registry with physician-certified causes of death (coded using ICD-9 and ICD-10). 
All data sources were linked with a deterministic algorithm using patients’ NHS number 
(unique ten-digit identifier assigned at first interaction with the healthcare system), date of 
birth, gender and postcode. 
 
Patients were selected from general practices (CPRD January 2017 version) that were eligible 
for linkage to HES and ONS, during the study period 1st April 1997 to 29th February 2016. 
Patients were included if they met the inclusion criteria described above.  
Confounders 
For each prescription for macrolide antibiotics or penicillin, the most recent information on 
potential confounders for each participant recorded up to the time of that prescription was 
obtained; thus values could change over time. Demographic information, including the age and 
sex of the patient, body mass index (BMI) recorded in primary care, and clinically-recorded 
smoking status and alcohol consumption, was obtained. For BMI, smoking and alcohol data, 
the last available measurement prior to the relevant prescription was taken; sensitivity analyses 
instead used the last measurement only if it was recorded within one year of the relevant date. 
We additionally included information about the region (Strategic Health Authority) in which 
the general practice was located, socioeconomic status using the Index of Multiple Deprivation 
(IMD) score and the frequency of primary care consultations involving clinical contact between 
the patient and their general practitioner. Missing data for demographic and socioeconomic 
confounders was handled by including an extra category indicating the information was not 
available. Phenotyping algorithms previously developed by the CALIBER initiative 16 were 
used to identify any prior use of: antidepressants, warfarin or digoxin, anti-arrhythmic drugs, 
anticoagulants, antiplatelet drugs, -adrenoceptor blockers, lipid regulating drugs, diuretics, 
nitrates, non-steroidal anti-inflammatories (NSAIDs) and anti-hypertensive drugs including 
angiotensin-converting enzyme inhibitors. Prior diagnoses of: atrial fibrillation, cancer, COPD, 
diabetes, dyslipidaemia, hypertension, cardiovascular disease, and asthma, were also identified 
using existing algorithms 16.  
 
Statistical analysis 
Most patients received multiple courses of macrolide antibiotics, penicillin, or both. To handle 
this, an approach in which the observational data are used to emulate a consecutive series of 
randomised trials was adopted for the statistical analysis 19. The study period was split into 
non-overlapping 30-day periods (giving 219 time intervals). Each of these 30-day intervals was 
considered the recruitment period for a different observational pseudo-trial. At the first instance 
during the 30-day interval where a patient was prescribed either a macrolide antibiotic or a 
penicillin, the patient was assessed for eligibility. If eligible at that point, the patient entered 
that pseudo-trial. Instances where both a macrolide antibiotic and a penicillin were prescribed 
simultaneously were excluded.  
 
Patients were eligible to enter a pseudo-trial if they were, at the time of the relevant prescription 
of macrolide or penicillin: between 16 and 80 years of age, were deemed to have had a 
diagnosis of CRS prior to that time, and had no recorded antibiotic prescription of any type in 
the last four weeks (a washout period). Patients could enter each pseudo-trial only once, but 
could enter multiple pseudo-trials over the whole study period.  
 
Data on all confounders listed above were recorded for each patient entering each pseudo-trial, 
with the values of the confounder determined at the date of the relevant prescription; thus 
confounder data were updated over time for each patient. Follow-up of a patient in a particular 
pseudo-trial began at the day of the relevant macrolide or penicillin prescription, and ended at 
the first of: the outcome of interest, death (for outcomes other than all-cause mortality), and 
end of patient-level follow-up.  
 
Descriptions of the participants, and summaries of outcome data, were performed at the patient 
level, initially restricting data to the first pseudo-trial each patient participated in. For 
subsequent analysis, data from the 219 different pseudo-trials were pooled together. 
Associations of exposure – prescription of macrolide antibiotic or penicillin – with health 
outcomes was assessed using Cox proportional hazards regression models, with time since 
entering the relevant pseudo-trial as the timescale. These Cox models adjusted for all 
confounders listed above. Age at entry into the pseudo-trial was modelled using restricted cubic 
splines. Differences between pseudo-trials were also modelled by using splines. Robust 
standard errors, adjusted for clustering by patient, were used due to the fact that patients could 
enter more than one pseudo-trial and so enter the analysis more than once. Sensitivity analyses 
censored follow-up at 30 days, to investigate short-term effects following prescription. For 
analyses of myocardial infarction censoring follow-up at 30 days, number needed to harm 
(NNH) was calculated by fitting a logistic regression model, approximately equivalent to the 
Cox model above, and calculating the NNH from the predicted risk under macrolide and no 
macrolide use, using 100 non-parametric bootstrap samples to obtain percentile confidence 
intervals. 
 
Public and patient involvement (PPI) 
Patients and public have been key to the development of a wider programme in which this 
study is embedded. Our PPI panel includes 7 patient and 5 lay representatives. A trained PPI 
facilitator has structured and led the face-to-face group meetings with the panel, ensuring that 
feedback has been well integrated into the programme of research. The panel has shared 
experiences of CRS and opinions regarding medical and surgical treatments they have 
received, and identified where they thought research was most needed to inform optimal 







Of the 88,321 patients who were identified as having CRS in this cohort, 70,369 were 
prescribed one or more courses of either a macrolide antibiotic (of any type) or penicillin, or 
both (Figure 1). Among these 70,369 patients, the median number of penicillin and macrolide 
courses prescribed was 4 (25th to 75th percentile: 2 to 8). A single prescription of either 
penicillin or macrolide during follow-up was received by 10% of these patients; more than 14 
prescriptions were received by 10% of patients. After restricting to prescriptions where the 
patient was eligible for a pseudo-trial, the final analysis included 66,331 unique patients, 
23,465 of whom contributed to the macrolide exposure group and 57,876 to the penicillin group 
(thus 15,010 entered the analysis both following a macrolide prescription and a penicillin 
prescription). A total of 320,798 prescriptions were included in the final analysis.  
 
Descriptive data 
Of the included 320,798 prescriptions, the most common duration was 1 week: 68% of 
penicillin prescriptions, 68% of macrolide, and 76% of clarithromycin were for 1 week. Almost 
all prescriptions were either 250mg or 500mg. For penicillin, 55.4% of prescriptions were for 
500mg and 43.5% 250mg. For macrolide prescriptions, 35.6% were 500mg and 64.3% 250mg. 
Restricting to clarithromycin, 61.2% of prescriptions were for 500mg and 38.8% 250mg. 
Amoxicillin, Flucloxacillin, and Co-amoxicillin accounted for more than 90% of the included 
Penicillin prescriptions, with 68% being for Amoxicillin (500 or 250mg), 12% for 
Flucloxacillin (500 or 250mg), and 10.9% for Co-amoxicillin (500, 250, or 125mg). The data 
used are collected for clinical care rather than research; as such, the indication the drug was 
prescribed for is not available.  
 
Recorded characteristics of participants, at the time of their first eligible macrolide or penicillin 
prescription were very similar (Table 1). Overall, females, patients with prior use of 
antidepressants, a history of chronic obstructive pulmonary disease or asthma were more likely 
to receive a macrolide antibiotic, but these differences were fairly small.   
 
Outcome data 
Median patient follow-up was 4.24 years (25th to 75th percentile: 2.0 to 7.4 years). Patients 
receiving a clarithromycin prescription tended to have shorter follow-up (Table 2). Patients 
included in the analysis participated in a median of 3 of the pseudo-trials (25th to 75th percentile: 
2 to 6).  
 
Over the whole follow-up period, 3,251 deaths due to any cause were observed, 815 of which 
were due to cardiovascular causes (Table 2). There were 925 incident myocardial infarctions, 
859 incident strokes, 637 incident diagnoses of peripheral vascular disease, and 1,436 recorded 
incident cardiac arrhythmias. Of these incident myocardial infarctions, 91 (9.8%) occurred on 
the date of the cardiac death; 56 (6.5%) of the incident strokes occurred on the date of the 
cardiac death.  
 
Main results 
Table 3 shows estimated hazard ratios (HRs), both unadjusted and adjusted for all confounders 
listed previously, associated with a prescription of a macrolide antibiotic compared with a 
prescription for penicillin. At the 5% level, no statistically significant short- or long-term risks 
were observed after adjustment for confounders.  
 
The unadjusted analysis showed no evidence of increased risk of myocardial infarction 
following macrolide prescription (crude hazard ratio (HR) 1.10, 95% confidence interval (CI): 
0.94 to 1.29, p=0.25). Following adjustment for all confounders above, the estimated hazard 
ratio for myocardial infarction during the first 30 days following prescription was 1.60, i.e. a 
60% increase in risk, with a confidence interval from 0.95 to 2.68, p=0.08. The estimated 
absolute risk of myocardial infarction within 30 days, per 10,000 patients, is 2.32 (95% CI: 
1.84, 2.90) with no macrolide prescription, and 3.75 (95% CI: 2.50, 5.24) with macrolide 
prescription, corresponding to a number needed to harm (i.e. number of patients needing to be 
treated with macrolides in order to result in a single extra myocardial infarction) of 7008 (95% 
CI: 3381, ). 
 
No evidence of a longer-term risk of myocardial infarction was seen (fully adjusted HR 1.09, 
95% CI: 0.93 to 1.28, p=0.30). Sensitivity analyses using BMI, smoking and alcohol 
information only if recorded within the last year gave similar results. 
 
Large increased risks were seen in the HRs following clarithromycin prescription, compared 
with penicillin, in the unadjusted models: all-cause death 1.26 (95% CI 1.12 to 1.42); cardiac 
death 1.34 (95% CI 1.04 to 1.72).  These estimated HRs were greatly diminished following 
adjustment and were no longer statistically significant: all-cause death 1.09 (95% CI 0.96 to 






Looking at a defined population of patients with CRS, we found a trend towards an increase in 
short-term risk of myocardial infarction in the 30 days following prescription of macrolides 
that did not reach statistical significance, especially with reference to clarithromycin. 
Specifically, our best estimates suggest macrolide prescription being associated with a 60% 
increase in hazard of myocardial infarction; our data are compatible with macrolide 
prescription being associated with a small reduction in hazard (up to 5% reduction), or with up 
to a 2.7-fold increase in hazard. No evidence of other short or long-term associations was found. 
Using contemporary electronic health records from national sources such as the Clinical 
Practice Research Datalink and Hospital Episode Statistics enabled us to analyse a 
representative section of the population and therefore our results are generalizable to the UK 




Confounding by indication is a key problem in observational studies like these. Our study 
population – patients flagged as having CRS – provides a more homogeneous group of 
individuals which may reduce this bias. Nonetheless, strong confounding was observed in 
analyses comparing clarithromycin prescriptions to penicillin; large crude associations 
between clarithromycin prescription and mortality were observed, which were removed after 
adjustment for potential confounders. Choosing an active comparator, rather than comparing 
with the absence of a macrolide prescription, minimises such biases; however it is possible that 
some confounding by indication remains. For example, patients with more severe or recurrent 
infections may be more likely to be prescribed macrolides rather than penicillin, and severity 
of infection may itself increase the risk of cardiovascular events, particularly in the short term. 
Thus the suggestion of a short-term increase in risk of myocardial infarction following 
macrolide prescription may simply reflect such residual confounding by indication.  
 
Our study was limited by the number of events which occurred during follow-up. Some of the 
analyses, especially when restricting to prescriptions for clarithromycin versus penicillin, had 
few events and thus suffered from low statistical power. In particular, uncertainty remains 
about the possible association between macrolide prescription and risk of myocardial infarction 
in this patient population.   
 
Diagnoses for chronic rhinosinusitis are not well recorded in electronic health record data. 
Although we developed an algorithm to determine which patients were likely to have CRS, 
based on primary and secondary diagnosis data and secondary care procedures, it is possible 
that the analysis may have omitted some patients with this condition, and included some who 
did not actually have CRS. This misclassification of case status is unlikely to have biased 
results, since it is unlikely that cardiovascular effects of macrolide antibiotics differ greatly for 
patients who have CRS.  
 
As with all analyses relying on electronic health records and administrative data, the quality of 
the data is a limiting factor. However, sensitivity analyses exploring the impact of missing data 
showed our results were robust to these missing data.   
 
We were unable to look specifically at longer duration low dose prescriptions of macrolide 
antibiotics, due to sample size constraints. Future studies are required to assess associations in 
this setting.  
 
Comparison with other studies 
Since 2006, a series of studies have raised concerns about possible cardiovascular risk 
associated with short term macrolide use. Our results, though not significant at the 5% level, 
are broadly consistent with those from Root et al. 12, and Wong et al. 13, who found some 
evidence of a short term association of clarithromycin and incident myocardial infarction but 
no long-term risks in patients receiving Helicobacter pylori treatment 12 and in the general 
Hong Kong population 13. In contrast to other studies 6-9, we found no evidence of increased 
risks of other events or longer term risks.  In particular, unlike other studies, we found no 
evidence of any increased risk of cardiovascular mortality 6, 8, 9, 11. One reason for these apparent 
discrepancies may be that these studies have predominantly investigated associations in 
populations with pre-existing heart conditions.  In contrast, we investigated incident 
myocardial infarction, stroke, diagnosis of peripheral vascular disease and cardiac arrhythmia, 
thus restricting these analyses to populations with lower frequency of pre-existing heart 
disease. It is possible that these associations truly differ in those different populations.  
 
Previous database studies have tended to be larger than ours, due to our additional restriction 
to a particular patient subgroup – patients with CRS. This limited our power to look at, for 
example, analyses restricted to clarithromycin rather than all macrolides.  
 
Clinical implications 
In summary, while our results were not statistically significant, our best estimates suggest a 
possible increased short-term risk of myocardial infarction in patients with CRS following 
prescription with macrolide antibiotics; this was less so for clarithromycin specifically. This 
supports prior observational evidence from different patient groups, and fits with physiological 
data of the impact of macrolides on the heart. However, confounding by indication remains a 
possible explanation for the apparent increase in risk. We found no evidence of any long-term 
increased risks. 
 
The MACRO Programme has been funded by the National Institute of Health Research to 
define best management of adults with CRS and will include a randomised controlled trial 
comparing a 12 week course of clarithromycin, placebo and sinus surgery starting in September 
2018. The trial will screen potential participants for any absolute contraindications to 
clarithromycin: risk factors including history of ischaemic heart disease, prolonged Q-T 
interval on ECG, diabetes and age over 65 or any medications known to interact with 
clarithromycin unless these can be discontinued during the 3 months of clarithromycin/placebo 
treatment. Based on the findings of this study, we have taken the necessary precautions to 
screen patients for the forthcoming trial, however, further guidance on when to prescribe 
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Table 1. Characteristics of patients in the first pseudo-trial they were eligible for,  







 Freq. % Freq. % Freq. % 
Age-group       
                 <40 15,149 28.3 3,300 25.7 1,218 23.0 
                 40-<50 11,369 21.3 2,921 22.8 1,194 22.5 
                 50-<60 11,563 21.6 2,854 22.2 1,209 22.8 
                 60-<70 9,687 18.1 2,396 18.7 1,075 20.3 
                 70-80 5,730 10.7 1,362 10.6 603 11.4 
Sex       
                 Male 19,919 37.2 4,148 32.3 1,876 35.4 
                 Female 33,579 62.8 8,685 67.7 3,423 64.6 
Smoking       
                 Non 24,649 46.1 6,018 46.9 2,393 45.2 
                 Ex 15,157 28.3 3,679 28.7 1,745 32.9 
                 Current 9,894 18.5 2,398 18.7 994 18.8 
                 Unknown 3,798 7.1 738 5.8 167 3.2 
Alcohol       
                 None 7,353 13.7 1,883 14.7 777 14.7 
                 Ex 2,529 4.7 686 5.3 322 6.1 
                 <1/week 10,798 20.2 2,778 21.6 1,172 22.1 
                 Current 2,256 4.2 513 4.0 207 3.9 
                 Excess 518 1.0 119 0.9 48 0.9 
                 Unknown 30,044 56.2 6,854 53.4 2,773 52.3 
BMI       
                 Underweight 828 1.5 206 1.6 95 1.8 
                 Normal 18,642 34.8 4,554 35.5 1,798 33.9 
                 Overweight 16,942 31.7 3,921 30.6 1,683 31.8 
                 Obese I 7,346 13.7 1,889 14.7 822 15.5 
                 Obese II 3,869 7.2 1,039 8.1 445 8.4 
                 Unknown 5,871 11.0 1,224 9.5 456 8.6 
Ethnicity       
                 White 31,646 59.2 7,856 61.2 3,362 63.4 
                 Indian 705 1.3 175 1.4 78 1.5 
                 Black 396 0.7 86 0.7 32 0.6 
                 China 244 0.5 58 0.5 23 0.4 
                 Mixed 482 0.9 124 1.0 56 1.1 
                 Unknown 20,025 37.4 4,534 35.3 1,748 33.0 
IMD       
                 1 (least deprived) 13,916 26.0 3,352 26.1 1,382 26.1 
                 2 12,214 22.8 2,974 23.2 1,219 23.0 
                 3 11,257 21.0 2,691 21.0 1,147 21.6 
                 4 9,077 17.0 2,186 17.0 918 17.3 
                 5 (most deprived) 6,984 13.1 1,623 12.6 629 11.9 
                 Missing 50 0.1 7 0.1 4 0.1 
 
Region 
      
   North East 1,157 2.2 219 1.7 86 1.6 
   North West 9,393 17.6 2,077 16.2 852 16.1 
   Yorkshire 2,477 4.6 555 4.3 202 3.8 
   East Midlands 1,661 3.1 416 3.2 88 1.7 
   West Midlands 6,693 12.5 1,521 11.9 722 13.6 
   East 6,490 12.1 1,515 11.8 583 11.0 
   South West 6,369 11.9 1,468 11.4 651 12.3 
   South Central 7,184 13.4 1,629 12.7 670 12.6 
   London 5,934 11.1 1,605 12.5 620 11.7 
   South East 6,140 11.5 1,828 14.2 825 15.6 
Prior use of:       
   Antidepressants 23,042 43.1 6,007 46.8 2,603 49.1 
   Warfarin or Digoxin 1,449 2.7 314 2.4 151 2.8 
   Antiarrhythmic drugs 5,361 10.0 1,412 11.0 599 11.3 
   Anticoagulants 1,491 2.8 348 2.7 174 3.3 
   Antiplatelets 6,567 12.3 1,526 11.9 655 12.4 
  -adrenoceptor blocking drugs 12,052 22.5 2,955 23.0 1,247 23.5 
   Lipid regulating drugs 8,180 15.3 2,000 15.6 949 17.9 
   Diuretics 10,308 19.3 2,682 20.9 1,137 21.5 
   Nitrates 8,700 16.3 2,145 16.7 926 17.5 
   Non-steroidal anti-inflammatories  37,544 70.2 9,258 72.1 3,889 73.4 
   Antihypertensive drugs 10,760 20.1 2,604 20.3 1,181 22.3 
History of:       
   Atrial fibrillation 916 1.7 186 1.4 94 1.8 
   Cancer 3,540 6.6 947 7.4 460 8.7 
   Chronic Obstructive Pulmonary 
Disease 
23,550 44.0 6,210 48.4 2,639 49.8 
   Diabetes 2,432 4.5 630 4.9 276 5.2 
   Dyslipidaemia 5,025 9.4 1,271 9.9 587 11.1 
   Hypertension 10,988 20.5 2,705 21.1 1,210 22.8 
   Cardiovascular disease 3,220 6.0 695 5.4 302 5.7 
   Asthma 13,252 24.8 3,719 29.0 1,543 29.1 









 Table 2. Outcome and follow-up data for participants in the pseudo-trials, 

















Follow-up (years) 5.1 (2.3, 8.8) 5.2  (2.3, 8.9) 4.8  (2.2, 8.6) 3.3 (1.5, 6.0) 
Number of trials participated in 3 (2, 6) 3 (2, 6) 3 (1, 6) 2 (1, 5) 
         
Outcome events Freq.   % Freq.   % Freq.   % Freq.   % 
Death by any cause 3,251 4.9 2,653 5.0 598 4.7 207 3.9 
Cardiovascular death 815 1.2 694 1.3 121 0.9 34 0.6 
Myocardial infarction 925 1.4 742 1.4 183 1.4 52 1.0 
Stroke 859 1.3 700 1.3 159 1.2 46 0.9 
   Ischaemic 498 0.8 410 0.8 88 0.7 27 0.5 
   Intracerebral haemorrhage 110 0.2 88 0.2 22 0.2 6 0.1 
   Subarachnoid haemorrhage 94 0.1 74 0.1 20 0.2 4 0.1 
   Not classified 370 0.6 290 0.5 80 0.6 26 0.5 
Peripheral vascular disease  637 1.0 514 1.0 123 1.0 36 0.7 
Cardiac arrhythmia 1,436 2.2 1,148 2.1 288 2.2 86 1.6 




   
Table 3. Crude and fully adjusted hazard ratios estimated from Cox models  




 HR 95% CI P HR 95% CI P 
Mortality       
Unadjusted 1.04 (0.95, 1.13) 0.446 1.26 (1.12, 1.42) <0.001 
Overall, adjusteda 0.99 (0.91, 1.09) 0.865 1.09 (0.96, 1.22) 0.181 
Censored at 30 days, adjusteda 0.93 (0.70, 1.24) 0.628 0.91 (0.62, 1.34) 0.639 
Cardiovascular Mortality       
Unadjusted 1.01 (0.83, 1.23) 0.890 1.34 (1.04, 1.72) 0.023 
Overall, adjusteda 1.00 (0.82, 1.21) 0.961 1.15 (0.89, 1.49) 0.272 
Censored at 30 days, adjusteda 0.99 (0.56, 1.77) 0.983 0.65 (0.24, 1.76) 0.394 
Myocardial infarction       
Unadjusted 1.10 (0.94, 1.29) 0.252 1.16 (0.91, 1.47) 0.226 
Overall, adjusteda 1.09 (0.93, 1.28) 0.300 1.04 (0.83, 1.32) 0.713 
Censored at 30 days, adjusteda 1.60 (0.95, 2.68) 0.077 1.22 (0.55, 2.67) 0.626 
Stroke       
Unadjusted 1.09 (0.93, 1.29) 0.280 1.16 (0.91, 1.48) 0.228 
Overall, adjusteda 1.06 (0.87, 1.29) 0.545 1.01 (0.78, 1.31) 0.947 
Censored at 30 days, adjusteda 1.11 (0.60, 2.05) 0.735 0.82 (0.33, 2.05) 0.670 
Diagnosis of Peripheral 
Vascular Disease 
      
Unadjusted 1.09 (0.92, 1.28) 0.309 1.15 (0.90, 1.46) 0.267 
Overall, adjusteda 0.99 (0.81, 1.22) 0.935 0.80 (0.63, 1.01) 0.060 
Censored at 30 days, adjusteda 1.03 (0.57, 1.89) 0.915 0.68 (0.24, 1.87) 0.453 
Cardiac Arrhythmia       
Unadjusted 1.10 (0.94, 1.30) 0.239 1.15 (0.90, 1.47) 0.250 
Overall, adjusteda 1.01 (0.88, 1.17) 0.851 0.99 (0.82, 1.19) 0.923 
Censored at 30 days, adjusteda 0.87 (0.58, 1.30) 0.491 0.85 (0.49, 1.49) 0.573 
HR Hazard ratio; CI confidence interval; P Wald-test p-value using robust standard error clustered on patient. 
a Adjusted for: pseudo-trial (splines), age (splines), gender, region of GP, IMD, smoking status, alcohol 
consumption, BMI group, contact with GP, prior use of drugs (see list in text), prior comorbidities (see list in 
text).  
 
 
